重要内容提示： 证券代码：603963 证券简称：大理药业 公告编号：2023-034 大理药业股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 7 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 156,248,500 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 71.1190 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由公司董事会召集，董事长杨君祥先生主持，采用现场投票与网络 (一) 累积投票议案表决情况 1、 关于选举公司第五届董事会非独立董事的议案 | 议 | 案 | 议案名称 | 得票数 | 得票数占出席 | 是 否 | | --- | --- | --- | --- | --- | --- | | 序号 | | | | 会议有效表决 权 ...

证券代码：603963 证券简称：大理药业 公告编号：2023-035 大理药业股份有限公司 关于第五届董事会第一次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 大理药业股份有限公司（以下简称"公司"）第五届董事会第一次会议于 2023 年 8 月 8 日下午以现场结合通讯方式召开，全体出席董事一致同意豁免本 次会议提前 5 日发出会议通知。本次会议应到董事 9 名，实到董事 8 名，其中董 事尹翠仙以通讯方式出席，董事曾立华因工作原因委托董事曾继尧对会议审议的 议案进行表决。经公司半数以上董事共同推举，本次会议由杨君祥先生主持。本 次会议的召集、召开和表决符合《中华人民共和国公司法》（以下简称"《公司 法》"）和《大理药业股份有限公司章程》（以下简称"《公司章程》"）的规 定。现将会议审议通过事项公告如下： 一、 审议通过《关于选举公司第五届董事会董事长的议案》 公司第五届董事会成员已经 2023 年第一次临时股东大会选举产生。根据《公 司法》、《公司章程》等相关规定，会议选举杨君祥先生为公司第五届董 ...

大理药业股份有限公司第五届董事会第一次会议独董意见 大理药业股份有限公司独立董事 姚荣辉: 李玉兰: A 董全亮: 二〇二三年八月八日 经了解被提名人的教育背景、工作经历和身体状况，其具备相应的任职资格, 能够胜任所聘任岗位职责的要求,有利于公司发展。 因此，同意聘任杨君祥先生为公司总经理;聘任李绍云先生为公司副总经理、 财务总监;聘任吴佩容女士为公司董事会秘书。 [本页以下无正文,下页起为签章页] 大理药业股份有限公司第五届董事会第一次会议独董意见 [此页无正文,为大理药业股份有限公司独立董事对第五届董事会第一次会议相关 事项的独立意见之签章页] 对第五届董事会第一次会议相关事项的独立意见 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共和 国证券法》、中国证监会《上市公司独立董事规则》、《大理药业股份有限公司章 程》(以下简称"《公司章程》")、《大理药业股份有限公司独立董事工作制度》 等有关规定,我们作为大理药业股份有限公司的独立董事,基于本人的独立判断, 对公司第五届董事会第一次会议审议的《关于聘任公司总经理的议案》、《关于聘 任公司副总经理的议案》、《关于聘任公司财务总监的议案》 ...

证券代码：603963 证券简称：大理药业 公告编号：2023-018 大理药业股份有限公司 关于参加云南辖区上市公司 2022 年度投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，大理药业股份有限公司（以下简称"公 司"）将参加由云南证监局、云南省上市公司协会与深圳市全景网络有限公司联 合举办的"2022 年度云南辖区上市公司投资者网上集体接待日暨集体业绩说明 会"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023 年 5 月 11 日（周四）10:30-12:00。 届时，公司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营 状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 资者踊跃参与！ 特此公告！ 大理药业股份有限公司董事会 2023 年 5 ...

Financial Performance - The company's operating revenue for 2022 was ¥132,344,033.67, representing a decrease of 22.83% compared to ¥171,493,284.80 in 2021[21]. - The revenue after deducting non-main business income was ¥132,325,176.51, also reflecting a 22.83% decrease from ¥171,470,999.07 in the previous year[21]. - The company reported a net profit attributable to shareholders of -17,701,547.25 RMB for 2022, a decrease from -41,890,560.38 RMB in 2021, showing a significant improvement[22]. - The operating cash flow for the year was -3,728,686.33 RMB, compared to a positive cash flow of 10,509,275.48 RMB in the previous year, indicating a decline of 135.48%[22]. - Total assets decreased by 8.25% year-on-year, from 548,746,054.41 RMB in 2021 to 503,486,467.80 RMB in 2022[22]. - The basic earnings per share for 2022 was -0.08 RMB, compared to -0.19 RMB in 2021, reflecting a reduction in losses[23]. - The weighted average return on equity improved to -4.32% in 2022 from -9.42% in 2021, an increase of 5.1 percentage points[23]. - The company's total profit for the period was CNY -16.99 million, with a net profit attributable to shareholders of CNY -17.70 million[70]. - Operating costs increased by 25.78% to CNY 57.79 million, primarily due to a decline in sales volume and production losses being reported in operating costs[71]. Governance and Compliance - The company has a commitment to ensure the accuracy and completeness of the annual report, with no false records or misleading statements[9]. - The audit report issued by Xinyong Zhonghe Accounting Firm was a standard unqualified opinion[4]. - The company has not violated decision-making procedures in providing guarantees[7]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with corporate governance regulations[160]. - The company has established a comprehensive governance structure, including various committees to ensure independent operation and decision-making[159]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating compliance with regulations[176]. Risk Management - There were no significant risks that materially affected the company's operations during the reporting period[8]. - The company has outlined various risks and countermeasures in its management discussion and analysis section[8]. - The company is cautious about implementing certain fundraising projects due to pressures from new pharmaceutical regulations and healthcare cost controls, planning to reassess these projects when the policy environment stabilizes[153]. - The company faces risks related to not winning bids in centralized procurement, which could adversely affect sales in public hospitals[139]. - The company is implementing cost reduction measures across production, procurement, and transportation to enhance efficiency[137]. Research and Development - The total research and development expenses amounted to 926,988.83 yuan, accounting for 0.70% of the operating revenue, with no capitalized R&D expenses reported[88]. - The company has 18 ongoing research projects, including safety re-evaluation of Huangqi injection and basic research on Xingnaojing injection, with significant progress reported[109]. - The company is focusing on research and development to improve innovation capabilities and product structure optimization[136]. - The company is conducting quality standard improvement research for its key products, including the Xingnaojing injection and the Cebuphosphocholine injection[111]. - The company’s R&D investment capitalized ratio for the company is 0%, indicating all R&D expenses were expensed in the period[117]. Market Strategy - The company plans to strengthen marketing efforts and expand into untapped markets to mitigate adverse effects from policy changes[33]. - The company is actively developing sales in private medical institutions and third-party markets to enhance its market presence[120]. - The company is exploring new strategies to improve product quality and competitiveness, including signing distribution agreements with major pharmaceutical companies[144]. - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[172]. - The company plans to enhance its distribution network, expecting a 15% reduction in logistics costs[172]. Product Development and Quality - The company has collaborated with Wenzhou Medical University and Jiangxi Academy of Forestry Sciences to enhance the production and quality research of its XNJ injection, ensuring the use of high-quality raw materials[36]. - The company has resumed the production of Astragalus injection to increase product variety and improve operational performance and profitability[39]. - The company emphasizes quality management and has established a comprehensive procurement system to ensure the supply of raw materials[56]. - All products are produced in strict accordance with GMP standards, with production plans adjusted based on market demand[57]. - The company is actively enhancing brand influence through academic promotion and ensuring clinical medication safety, which supports sustained healthy sales growth[142]. Financial Management - The company has a total of ¥62,496,374.73 in restricted assets, including fixed assets of ¥22,453,799.99, intangible assets of ¥23,655,674.01, and investment properties of ¥16,386,900.73, all secured by loans[95]. - The company’s financial expenses surged by 1823.74%, reaching 889,647.56 yuan, mainly due to the capitalization of interest expenses after the completion of the technology complex[87]. - The company’s total investment in bank financial products at the end of the period was CNY 229,233,216.72, reflecting a strategic approach to asset management[129]. - The company plans to continue its strategy of using idle funds for financial products, indicating a focus on optimizing asset management[182]. Employee Management - The total number of employees in the parent company and major subsidiaries is 289, with 120 in production, 44 in sales, and 84 in technical roles[197]. - Employee training plans are established annually to enhance professional skills and align with company development needs, combining internal and external training methods[199]. - The company emphasizes a multi-skilled workforce, encouraging employees to take on multiple roles and responsibilities[200]. - The company revised its compensation policy in 2022 to align with national policies and operational conditions, incorporating various salary components[198]. Strategic Initiatives - The company is investing 100 million yuan in research and development for innovative drug formulations over the next two years[168]. - A strategic acquisition of a smaller pharmaceutical company was completed, valued at 300 million yuan, aimed at enhancing product offerings[168]. - The company plans to enhance its digital marketing strategy, allocating an additional 20 million yuan for online advertising campaigns[168]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 20% by 2025[172].

Financial Performance - The company's operating revenue for Q1 2023 was ¥36,887,280.13, representing a decrease of 7.36% compared to the same period last year[6]. - The net profit attributable to shareholders was -¥2,551,643.71, with a basic earnings per share of -¥0.0116[6]. - Total operating revenue for Q1 2023 was CNY 36,887,280.13, a decrease of 7.3% compared to CNY 39,816,703.15 in Q1 2022[17]. - Net loss for Q1 2023 was CNY -2,551,643.71, an improvement from a net loss of CNY -3,207,503.31 in Q1 2022, indicating a 20.4% reduction in losses[18]. - Gross profit margin for Q1 2023 was approximately -10.0%, compared to a margin of -7.0% in Q1 2022, highlighting a decline in profitability[17]. Assets and Liabilities - The total assets at the end of the reporting period were ¥490,390,642.70, down 2.60% from the end of the previous year[7]. - Total assets as of Q1 2023 were CNY 490,390,642.70, down from CNY 503,486,467.80 at the end of Q1 2022, a decline of 2.2%[17]. - Total liabilities for Q1 2023 were CNY 91,785,928.97, compared to CNY 102,330,110.36 in Q1 2022, representing a decrease of 10.3%[16]. - The total liabilities remained stable at CNY 101,560,127.69 as of January 1, 2023[24]. - Deferred tax liabilities were reported at 334,982.51, down from 446,557.60[25]. Cash Flow - The cash flow from operating activities was -¥5,206,773.92, primarily due to a decrease in cash paid for goods[9]. - In Q1 2023, the cash inflow from operating activities was CNY 40,925,167.74, a decrease of 1.56% compared to CNY 41,574,777.56 in Q1 2022[20]. - The net cash flow from operating activities was -CNY 5,206,773.92, an improvement from -CNY 6,173,987.51 in the same period last year[20]. - The cash inflow from investment activities totaled CNY 102,285,700.52, with a net cash flow of CNY 19,950,157.84, compared to a net outflow of -CNY 108,271,432.96 in Q1 2022[21]. - The cash paid for taxes increased significantly to CNY 6,791,496.84 in Q1 2023, compared to CNY 3,653,736.94 in Q1 2022, marking an increase of about 86.5%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,216[10]. - The top shareholder, Yang Junxiang, holds 24.20% of the shares, totaling 53,172,200 shares[11]. - The company's total equity attributable to shareholders was CNY 398,604,713.73 in Q1 2023, slightly down from CNY 401,156,357.44 in Q1 2022, a decrease of 0.4%[17]. Research and Development - Research and development expenses for Q1 2023 were CNY 151,998.65, significantly lower than CNY 347,576.35 in Q1 2022, a decrease of 56.3%[18]. - The company did not report any significant new product developments or market expansion strategies during this quarter[13]. Accounting Changes - The company has implemented new accounting standards starting January 1, 2023, affecting the recognition of deferred tax assets and liabilities[21].

证券代码：603963 证券简称：大理药业 公告编号：2023-016 大理药业股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 三、 参加人员 重要内容提示： 投资者可于 2023 年 4 月 28 日(星期五)至 5 月 9 日(星期二)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 dongban@daliyaoye.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 大理药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公 司 2022 年度报告、2023 年第一季度报告，为便于广大投资者更全面深入地了解 公司 2022 年度和 2023 年第一季度的经营成果、财务状况以及 2022 年度利润分 配方案，公司计划于 2023 年 5 月 10 日下午 15:00-16:00 举行 2022 年度暨 20 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥69,682,312.37, a decrease of 24.30% compared to ¥92,047,760.00 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was -¥8,490,734.57, compared to -¥1,173,047.39 in the previous year, indicating a significant loss[20]. - The net cash flow from operating activities was -¥9,579,308.38, compared to -¥8,406,435.48 in the same period last year[20]. - The total assets decreased by 5.09% to ¥520,834,215.16 from ¥548,746,054.41 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company decreased by 2.03% to ¥410,367,170.12 from ¥418,857,904.69 at the end of the previous year[20]. - The company reported a net profit excluding non-recurring gains and losses of -¥11,265,117.72, compared to -¥4,320,255.38 in the previous year[20]. - The basic earnings per share (EPS) for the first half of 2022 was -0.0386 CNY, a decrease from -0.0053 CNY in the same period last year[22]. - The diluted EPS for the same period was also -0.0386 CNY, reflecting a significant decline in profitability[22]. - The weighted average return on equity (ROE) decreased by 1.8 percentage points to -2.05%[22]. Operational Challenges - The company faced significant operational pressure in the first half of 2022 due to repeated pandemic impacts and centralized procurement results, leading to a decrease in terminal order volume[46]. - The company is actively adjusting its marketing strategies to stabilize existing markets and explore new ones in response to the challenges posed by the pandemic and procurement policies[50]. - The company faced risks from centralized procurement policies, impacting sales of key products like the "Cerebral Revitalizing Injection" which was not selected in recent procurement rounds[70]. - The company plans to adjust sales strategies for non-winning products and enhance efforts in private hospitals to mitigate the impact of procurement risks[70]. - The company faces risks from the implementation of new medical insurance policies, which may lower the drug proportion and impact sales, especially for auxiliary drugs[75]. - The trend of drug price reductions is expected to continue due to the new medical insurance directory and cost control measures, directly affecting the company's main revenue[76]. - The company is actively exploring new marketing strategies and enhancing product quality to mitigate the impact of declining drug prices and increase market share[77]. Research and Development - The company has established strategic partnerships with several universities and research institutions, enhancing its research and development capabilities[42]. - The company completed research projects on medicinal materials in collaboration with universities, enhancing product quality and standards[53]. - Research and development expenses increased by 30%, totaling 200 million yuan, focusing on innovative technologies[112]. Product and Market Strategy - The company has 20 varieties and 44 specifications of injectable drugs approved, with 16 varieties included in the National Basic Medical Insurance Directory[26]. - The main products include "Zhongjing®" Xinaojing Injection and Shenmai Injection, both of which are classified as essential medicines under national insurance[27]. - The company has established a direct distribution system to enhance market share and stabilize sales amid policy changes like volume-based procurement[33]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the fiscal year[112]. Financial Management - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for the reporting period[6]. - The company has not disclosed any significant risks that could materially affect its operations during the reporting period[7]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[7]. - The company has reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 20% year-over-year growth[112]. - The company reaffirmed its commitment to shareholder interests and transparency in financial reporting[115]. Environmental and Social Responsibility - The company donated 100,000 yuan to support rural revitalization efforts, reflecting its commitment to social responsibility[57]. - The company has reported that its wastewater and air emissions are within regulatory limits, with average COD concentration at 42 mg/L and total emissions of 0.3444 tons for the first half of the year[100][101][102]. - The company has achieved a solid waste treatment rate of 100% during the reporting period, ensuring compliance with environmental standards[102]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period was 32,321[125]. - The largest shareholder, Yang Junxiang, holds 56,023,500 shares, representing 25.50% of the total shares[127]. - The second-largest shareholder, Lixing Industrial Co., Ltd., holds 41,193,750 shares, accounting for 18.75%[127]. - The company reported no changes in total share capital or structure during the reporting period[124]. Regulatory Compliance - The management emphasized the importance of maintaining compliance with regulatory standards to avoid potential penalties[115]. - The company operates under the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[177]. - The company includes subsidiaries and structured entities under its control in the consolidated financial statements[183].

Financial Performance - The company's operating revenue for 2021 was ¥171,493,284.80, a decrease of 19.71% compared to ¥213,583,457.33 in 2020[21] - The net profit attributable to shareholders of the listed company was -¥41,890,560.38, representing a significant decline of 1,396.25% from ¥3,231,666.29 in the previous year[21] - The company reported a total revenue of 171.49 million yuan in 2021, a decrease of 19.71% compared to the previous year[30] - The net profit attributable to shareholders was -41.89 million yuan, a decline of 1,396.25% year-on-year[30] - The basic earnings per share for 2021 was -0.19 yuan, down from 0.01 yuan in 2020, representing a decrease of 2,000%[23] - The company recorded a cash flow from operating activities of -1.90 million yuan, a significant decrease from -6.50 million yuan in the previous year[25] - The total assets at the end of 2021 were 548.75 million yuan, down 5.18% from 578.71 million yuan at the end of 2020[22] - The company incurred an asset impairment provision of 31.62 million yuan during the reporting period, contributing to the decline in net profit and return on equity[23] - The weighted average return on equity was -9.42%, a decrease of 10.11 percentage points from the previous year[23] - The total profit amounted to CNY -41.59 million, reflecting a significant year-on-year decline of 1201.51%[66] Dividend and Shareholder Actions - The company did not distribute cash dividends, issue bonus shares, or convert capital reserves into share capital during the reporting period[5] - The company reported a total of 64,394,070 shares held by directors and senior management at the end of the reporting period, with no changes in shareholding during the year[168] - The total pre-tax remuneration for directors and senior management amounted to 461.42 million CNY for the reporting period[168] Compliance and Governance - The company has maintained compliance with financial reporting standards, as confirmed by the standard unqualified audit report from the accounting firm[4] - The company has established a comprehensive governance structure, ensuring independent operation of the board and compliance with legal requirements[162] - The board consists of 9 members, including 3 independent directors, ensuring diverse and effective decision-making[163] - The company emphasized its commitment to information disclosure and transparency, ensuring all shareholders receive equal access to information[164] - The company has not reported any significant differences in governance compared to regulatory requirements[164] - The company has not faced any major changes in competition or business independence issues with its controlling shareholders[164] - The company has implemented measures to ensure compliance with insider information regulations[164] Market and Product Development - The company plans to focus on new product development and market expansion in the upcoming year[6] - The company is actively cooperating with national standards improvement efforts, particularly in enhancing the quality standards for its products, which will boost market competitiveness[37] - The company is committed to developing new Chinese medicines based on ancient classic formulas and improving the efficacy of traditional Chinese medicine[47] - The company has developed 20 varieties and 44 specifications of injectable drugs, with 16 varieties included in the National Basic Medical Insurance Directory (2021 edition)[49] - Major products include "Zhongjing®" Xinaojing Injection and Shenmai Injection, both of which are classified as essential medicines under national insurance[50] - The company is actively seeking horizontal or vertical cooperation opportunities to achieve sustainable development goals[128] Research and Development - The company owns 29 valid patents, including 12 invention patents, and has registered 2 software copyrights during the reporting period[38] - The company is engaged in ongoing research to optimize production processes and improve the quality of its products, including the Yellow Qi injection and other formulations[36] - The R&D investment for the reporting period accounted for 0.84% of total revenue, significantly lower than the industry average of 8,034.19 million[112] - The company has made progress in the basic research of several products, including the Huangqi injection and Xingnaojing injection, with ongoing stability tests and quality standard improvements[109] - The company maintains a dual approach of independent and collaborative R&D to strengthen its product offerings in the cardiovascular field[107] Marketing and Sales Strategy - The company plans to enhance its marketing efforts and adjust sales strategies to stabilize and expand its market presence[33] - A nationwide marketing network has been established, focusing on direct distribution to stabilize sales and expand market share[57] - The company is focusing on deepening cooperation with major public medical institutions to enhance its distribution network and service recognition[132] - The company is enhancing its team building efforts by revising its human resources system and focusing on talent development and training[136] Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[10] - The company faces risks from centralized procurement policies, which could impact its market share if its products do not win bids in certain provinces[138] - The company is addressing the challenges posed by healthcare cost control measures by leveraging its leading products' efficacy and safety to maintain market presence[142] - The company is actively exploring strategies to enhance product quality and competitiveness in response to ongoing price declines and procurement models[145] Financial Management - The company reported a net cash flow from operating activities of CNY 10.51 million, a significant improvement from a negative cash flow of CNY -6.36 million in the previous year[68] - The net cash flow from investing activities is ¥90,667,185.92, compared to -¥32,350,104.54 in the previous year, mainly due to a decrease in the purchase of financial products[89] - The total debt was reduced by 10% to 400 million, improving the company's financial stability[170] Management Changes - The company appointed Yang Junxiang as the new General Manager, while Wang Hongxin resigned due to personal reasons[177] - The company experienced a change in independent directors, with Li Xiaojun resigning from his position[178] - The company has seen a significant turnover in management, with multiple resignations in key positions during the reporting period[178] Social Responsibility - The company donated RMB 100,000 to the Red Cross for earthquake relief and RMB 500,000 for disaster recovery efforts, demonstrating its commitment to social responsibility[39]

Financial Performance - The company's operating revenue for Q1 2022 was ¥39,816,703.15, representing a decrease of 18.74% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥3,207,503.31, reflecting a significant decline of 1,791.60% year-over-year[4] - The basic and diluted earnings per share were both -¥0.0146, a decrease of 1,722.22% compared to the previous year[4] - Total operating revenue for Q1 2022 was ¥39,816,703.15, a decrease of 18.7% compared to ¥48,999,329.56 in Q1 2021[16] - Net profit for Q1 2022 was a loss of ¥3,207,503.31, compared to a profit of ¥189,613.98 in Q1 2021[17] - Total revenue from sales of goods and services in Q1 2022 was 41,070,778.00 RMB, down 21.5% from 52,425,098.38 RMB in Q1 2021[20] - The company incurred a net loss attributable to the parent company of -3,207,503.31 RMB in Q1 2022, compared to a profit of 189,613.98 RMB in Q1 2021[18] - Basic and diluted earnings per share for Q1 2022 were both -0.0146 RMB, a significant decrease from 0.0009 RMB in Q1 2021[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥532,763,510.03, down 2.91% from the end of the previous year[5] - Total assets as of March 31, 2022, were ¥532,763,510.03, down from ¥548,746,054.41 at the end of 2021[15] - Total liabilities decreased to ¥117,113,108.65 in Q1 2022 from ¥129,888,149.72 in Q1 2021, a reduction of 9.9%[14] - Current assets totaled ¥336,026,750.19, a decrease of 3.5% from ¥348,545,191.59 at the end of 2021[13] - Cash and cash equivalents were ¥65,639,521.27, down from ¥180,658,755.50 at the end of 2021[12] - Cash and cash equivalents at the end of Q1 2022 were 65,639,521.27 RMB, a decrease from 180,658,755.50 RMB at the beginning of the quarter[22] Cash Flow - The cash flow from operating activities showed a net outflow of ¥6,173,987.51, indicating a decrease in cash received from sales[4] - In Q1 2022, the company reported a net cash flow from operating activities of -6,173,987.51 RMB, compared to -1,901,446.89 RMB in Q1 2021, indicating a decline in operational cash flow[21] - The total cash outflow from operating activities was 47,748,765.07 RMB in Q1 2022, compared to 55,509,429.77 RMB in Q1 2021, reflecting a reduction in cash outflow[21] - The company received 503,999.56 RMB in other cash related to operating activities in Q1 2022, down from 1,182,884.50 RMB in Q1 2021[21] - Cash outflow from financing activities in Q1 2022 was -573,813.76 RMB, a significant decrease from a net inflow of 9,705,722.22 RMB in Q1 2021[22] Investments - The company reported a significant decrease in cash and cash equivalents by 63.67%, primarily due to investments in financial products[7] - The company experienced a 76.68% increase in trading financial assets, attributed to the same investment strategy[7] - The company invested 100,000,000.00 RMB in Q1 2022, compared to no investment in Q1 2021, indicating a strategic shift towards investment activities[21] - The company reported a net cash flow from investing activities of -108,271,432.96 RMB in Q1 2022, compared to -5,657,380.27 RMB in Q1 2021, indicating increased investment expenditures[21] Operational Metrics - Total operating costs for Q1 2022 were ¥44,198,473.44, down 13.0% from ¥50,787,850.90 in Q1 2021[16] - The company reported a gross profit margin of -10.4% in Q1 2022, compared to a positive margin in Q1 2021[16] - Inventory decreased to ¥22,932,220.87 from ¥25,420,333.37, a decline of 9.8%[13] - Research and development expenses increased to ¥347,576.35 in Q1 2022 from ¥286,045.07 in Q1 2021, reflecting a growth of 21.5%[16] Government Support and Strategic Direction - The company received government subsidies amounting to ¥44,176.20 during the reporting period[6] - The company has not disclosed any new product developments or market expansion strategies in this report[11]